Medicalgorithmics S.A.: Dopuszczenie i warunkowe wprowadzenie do obrotuakcji serii I (2023-06-14)

Current Report No. 14/2023

Date of preparation: 2023-06-14

Abbreviated name of the issuer: MEDICALGORITHMICS S.A.

Subject: Admission and conditional introduction of the Company's series I shares to trading on the main market of the WSE. Setting the date of the first listing of the Company's series I shares after their assimilation with shares traded on the main market.

Legal basis: Art. 56 (1) (2) of the Act on Offering - current and periodic information.

Contents of the report:

The Management Board of MEDICALGORITHMICS S.A. with its seat in Warsaw [Issuer, Company], hereby informs that on June 14, 2023 it received information on the adoption of Resolution No. 562/2023 of the Management Board of the Warsaw Stock Exchange on June 14, 2023 [WSE] regarding the admission and introduction to trading on the WSE Main Market of series I ordinary bearer shares of the Company [Resolution].

Pursuant to the Resolution, 995,276 [nine hundred and ninety-five thousand two hundred and seventy-six] series I bearer common shares of the Company carrying ISIN code PLMDCLG00031 [Shares], with a nominal value of 0.10 [ten grosz] each, were admitted to trading on the main market. 

Pursuant to the Resolution, the Shares will be listed on the main market as of June 21, 2023, subject to the assimilation of the Shares by the National Securities Depository S.A. [Krajowy Depozyt Papierów Wartościowych SA] on June 21, 2023 with the Company's shares traded on the stock exchange, under the code PLMDCLG00015. The Company will announce the assimilation of the Shares in a separate current report.

The Company reminds that the Shares were issued in accordance with the Resolution No. 4 of the Company's Extraordinary General Meeting of October 28, 2022 Increase of the Company's share capital through issue of series I, J, K and L shares; waiver of existing shareholders’ subscription rights; private subscription offer for a designated entity; and change of Article 5 (1) and (2) of the Articles of Association. The shares were registered with the National Securities Depository on March 7, 2023, as the Company announced in current report number 8/2023 on March 8, 2023.

The Company reminds that in the current report No. 55/2022 it informed on October 1, 2022 that 4,976,384 Shares were acquired by Biofund Capital Management LLC with its registered office in Miami (USA). These shares are to be introduced to trading under the applicable exceptions to the obligation to prepare an issue prospectus, and the planned date of introducing all these shares to trading has been set at the end of 2026.